DR-299 MutSig – The incidence and co-ocurrence of genomic biomarkers in metastatic tumors
The observed incidence of cancer biomarkers can influence resource investment into key areas such as drug discovery and companion diagnostic technology. The list of clinically relevant cancer biomarkers is growing, however a systematic description of the incidence of these biomarkers is currently lacking. Understanding the prevalence of these biomarkers in late-stage cancer can be especially relevant since many companion diagnostics are utilized in the treatment of stage III and IV cancers.
By using multiple publicly available knowledge management resources that describe clinically relevant alterations, we aim to characterize the frequency of these biomarkers and contextualize their associations within the Hartwig dataset.
Eivind Hovig, University of Oslo, Norge
Back to newsMore news
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Accreditation renewed
In October 2020, we received formal notification of the renewal of our accreditation of ISO17025: 2005 into the 2017 version. We …
The Importance of Analyzing the DNA of Rare Tumors
One in four patients has a cancer type that is considered rare, meaning it occurs in fewer than six out …
The knowledge we gather with WGS can bring us a step closer to our goal to find an effective and suitable treatment for every single patient, not based on ‘one size fits all’, but adjusted to the characteristics of the patient and the tumor.